Compare Stocks: CMMB, BHST, APLM, and FTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$17.28 +0.2%	$17.34	$3.66 ▼ $42.12	$38.02M	1.46	13,915 shs	4,075 shs
BHST BioHarvest Sciences	$2.26 +4.6%	$2.92	$1.82 ▼ $12.80	$44.34M	0.98	33,752 shs	100,272 shs
CMMB Chemomab Therapeutics	$1.66 +2.5%	$1.71	$1.35 ▼ $4.12	$11.95M	0.65	92,724 shs	38,587 shs
FTH Sensei Biotherapeutics	$25.50 -6.7%	$0.00	$7.20 ▼ $37.90	$34.22M	-0.26	203,049 shs	651,931 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	+1.18%	-7.03%	-12.09%	+8.47%	+183.98%
BHST BioHarvest Sciences	0.00%	+6.40%	-24.74%	-48.69%	-71.91%
CMMB Chemomab Therapeutics	+4.52%	+14.08%	-28.63%	-0.61%	-60.49%
FTH Sensei Biotherapeutics	+0.37%	-6.50%	+19.28%	+2,733,999,900.00%	+2,733,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$17.28 +0.2%	$17.34	$3.66 ▼ $42.12	$38.02M	1.46	13,915 shs	4,075 shs
BHST BioHarvest Sciences	$2.26 +4.6%	$2.92	$1.82 ▼ $12.80	$44.34M	0.98	33,752 shs	100,272 shs
CMMB Chemomab Therapeutics	$1.66 +2.5%	$1.71	$1.35 ▼ $4.12	$11.95M	0.65	92,724 shs	38,587 shs
FTH Sensei Biotherapeutics	$25.50 -6.7%	$0.00	$7.20 ▼ $37.90	$34.22M	-0.26	203,049 shs	651,931 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	+1.18%	-7.03%	-12.09%	+8.47%	+183.98%
BHST BioHarvest Sciences	0.00%	+6.40%	-24.74%	-48.69%	-71.91%
CMMB Chemomab Therapeutics	+4.52%	+14.08%	-28.63%	-0.61%	-60.49%
FTH Sensei Biotherapeutics	+0.37%	-6.50%	+19.28%	+2,733,999,900.00%	+2,733,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	1.00	Sell	N/A	N/A
BHST BioHarvest Sciences	2.00	Hold	$10.00	342.48% Upside
CMMB Chemomab Therapeutics	2.00	Hold	$25.00	1,406.02% Upside
FTH Sensei Biotherapeutics	2.83	Moderate Buy	$54.90	115.29% Upside

Current Analyst Ratings Breakdown

Latest CMMB, BHST, APLM, and FTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
7/31/2026	FTH Sensei Biotherapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FTH Sensei Biotherapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
7/20/2026	FTH Sensei Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
7/16/2026	FTH Sensei Biotherapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	FTH Sensei Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$57.00
6/25/2026	FTH Sensei Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/23/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/22/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$60.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$8.50M	4.47	N/A	N/A	($2.89) per share	-5.98
BHST BioHarvest Sciences	$34.51M	1.28	N/A	N/A	$1.30 per share	1.74
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
BHST BioHarvest Sciences	-$11.14M	-$0.59	N/A	N/A	N/A	-32.54%	-76.03%	-25.30%	8/11/2026 (Estimated)
CMMB Chemomab Therapeutics	-$8.99M	-$2.22	N/A	N/A	N/A	N/A	-89.03%	-79.68%	8/13/2026 (Estimated)
FTH Sensei Biotherapeutics	-$21.08M	-$142.72	N/A	N/A	N/A	N/A	-83.59%	-256.50%	8/4/2026 (Estimated)

Latest CMMB, BHST, APLM, and FTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.04	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	BHST BioHarvest Sciences	-$0.13	N/A	N/A	N/A	$9.45 million	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$0.62	+$4.4250	-$0.62	N/A	N/A
5/15/2026	Q1 2026	FTH Sensei Biotherapeutics	N/A	-$131.45	N/A	-$131.45	N/A	N/A
5/15/2026	Q4 2025	FTH Sensei Biotherapeutics	-$0.62	-$131.45	-$130.83	-$131.45	N/A	N/A
5/14/2026	Q1 2026	BHST BioHarvest Sciences	-$0.13	-$0.11	+$0.02	-$0.11	$8.50 million	$8.51 million
5/14/2026	Q1 2026	CMMB Chemomab Therapeutics	-$0.04	-$0.22	-$0.18	$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	0.96	0.96
BHST BioHarvest Sciences	0.03	2.96	2.44
CMMB Chemomab Therapeutics	N/A	10.31	10.31
FTH Sensei Biotherapeutics	N/A	14.39	14.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
BHST BioHarvest Sciences	N/A
CMMB Chemomab Therapeutics	46.05%
FTH Sensei Biotherapeutics	10.50%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
BHST BioHarvest Sciences	N/A
CMMB Chemomab Therapeutics	11.91%
FTH Sensei Biotherapeutics	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	2.20 million	N/A	Not Optionable
BHST BioHarvest Sciences	N/A	19.62 million	N/A	N/A
CMMB Chemomab Therapeutics	20	7.20 million	6.34 million	Not Optionable
FTH Sensei Biotherapeutics	40	1.34 million	1.25 million	Not Optionable

CMMB, BHST, APLM, and FTH Headlines

Recent News About These Companies

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

August 4 at 7:30 AM | businesswire.com

Sensei Biotherapeutics (NASDAQ:FTH) Research Coverage Started at Raymond James Financial

August 3 at 2:24 AM | americanbankingnews.com

This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

July 31, 2026 | benzinga.com

Oppenheimer Initiates Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

July 30, 2026 | americanbankingnews.com

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2026 | businesswire.com

Brian Stephenson Acquires 831 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

July 2, 2026 | insidertrades.com

Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Purchases 6,250 Shares

June 27, 2026 | insidertrades.com

Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CEO Purchases $55,446.56 in Stock

June 25, 2026 | insidertrades.com

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

June 15, 2026 | businesswire.com

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 4, 2026 | businesswire.com

Most and least shorted healthcare stocks with market cap up to $2B at the end of May

June 3, 2026 | seekingalpha.com

Insider Selling: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells 25,000 Shares of Stock

June 2, 2026 | insidertrades.com

Cantor Fitzgerald initiates coverage of Sensei Biotherapeutics (SNSE) with overweight recommendation

May 30, 2026 | msn.com

Citigroup initiates coverage of Sensei Biotherapeutics (SNSE) with buy recommendation

May 24, 2026 | msn.com

Sensei Biotherapeutics Updates 2026 Board Reconstitution Plans

May 22, 2026 | tipranks.com

Millennium management reports $89k Sensei Biotherapeutics share sales

May 17, 2026 | investing.com

Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $164,021.22 in Stock

May 16, 2026 | insidertrades.com

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026 | businesswire.com

Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts

May 5, 2026 | finance.yahoo.com

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

May 5, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, BHST, APLM, and FTH Company Descriptions

Apollomics NASDAQ:APLM

$17.28 +0.03 (+0.18%)

Closing price 03:54 PM Eastern

Extended Trading

$17.74 +0.46 (+2.69%)

As of 04:10 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

BioHarvest Sciences NASDAQ:BHST

$2.26 +0.10 (+4.63%)

Closing price 04:00 PM Eastern

Extended Trading

$2.27 +0.01 (+0.44%)

As of 04:10 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Chemomab Therapeutics NASDAQ:CMMB

$1.66 +0.04 (+2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.04 (+2.11%)

As of 04:56 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Sensei Biotherapeutics NASDAQ:FTH

$25.50 -1.84 (-6.73%)

Closing price 04:00 PM Eastern

Extended Trading

$25.92 +0.41 (+1.63%)

As of 04:10 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, BHST, APLM, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, BHST, APLM, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, BHST, APLM, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, BHST, APLM, and FTH Company Descriptions

Apollomics NASDAQ:APLM

BioHarvest Sciences NASDAQ:BHST

Chemomab Therapeutics NASDAQ:CMMB

Sensei Biotherapeutics NASDAQ:FTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, BHST, APLM, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, BHST, APLM, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, BHST, APLM, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, BHST, APLM, and FTH Company Descriptions

Apollomics NASDAQ:APLM

BioHarvest Sciences NASDAQ:BHST

Chemomab Therapeutics NASDAQ:CMMB

Sensei Biotherapeutics NASDAQ:FTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools